Payment overview · 2025
General Payments
$1,312.02
63 reported records · 18 companies
Healthcare provider profile · identity verified
Dean Kravis, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · NILES, IL · NPI 1881620458
Verified facts
What the public records show
CMS Open Payments records show Dean Kravis, MD received $1,312.02 in general payments during 2025 across 63 reported records.
Lilly USA, LLC accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Farxiga, Jardiance, Ozempic, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Synthroid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Unithroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Afrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $187.95 | 14.3% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $184.10 | 14.0% | 10 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $160.40 | 12.2% | 6 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $144.14 | 11.0% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $139.17 | 10.6% | 6 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $113.99 | 8.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.35 | 8.2% | 5 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $47.60 | 3.6% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $32.83 | 2.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.65 | 2.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.38 | 2.2% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $26.79 | 2.0% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $22.64 | 1.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.06 | 1.4% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.26 | 1.4% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.44 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.21 | 1.2% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $15.06 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,305.37 | 62 |
| Education | $6.65 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $291.37 | 13 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $184.10 | 10 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $160.40 | 6 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $144.14 | 7 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $113.99 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.24 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.47 | 3 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $47.60 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $32.83 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.38 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 224 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 194 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
88 | 20 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
224 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
224 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
194 | 37 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl | Metformin Hcl | 270 | 70 |
| Jardiance | Empagliflozin | 224 | 43 |
| Glimepiride | Glimepiride | 215 | 47 |
| Ozempic | Semaglutide | 194 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 41 |
| Metformin Hcl Er | Metformin Hcl | 136 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 108 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 28 |
| Lisinopril | Lisinopril | 96 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 92 | 23 |
| Synthroid | Levothyroxine Sodium | 88 | 20 |
| Liothyronine Sodium | Liothyronine Sodium | 87 | 22 |
| Farxiga | Dapagliflozin Propanediol | 82 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 74 | 35 |
| Trulicity | Dulaglutide | 72 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 67 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 17 |
| Novolog Flexpen | Insulin Aspart | 62 | 14 |
| Gabapentin | Gabapentin | 56 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 53 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Unithroid | Levothyroxine Sodium | 49 | 14 |
| Simvastatin | Simvastatin | 47 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | suppressed |
| Omeprazole | Omeprazole | 40 | suppressed |
| Glipizide | Glipizide | 39 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 39 | 12 |
| Januvia | Sitagliptin Phosphate | 38 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Levoxyl | Levothyroxine Sodium | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | 13 |
| Methimazole | Methimazole | 24 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Losartan Potassium | Losartan Potassium | 23 | suppressed |
| Afrezza | Insulin Regular, Human | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Glipizide Xl | Glipizide | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 12 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,312.02 · 63 records | Lilly USA, LLC | AFREZZA, FARXIGA, ISTURISA, JARDIANCE, Korlym, MYCAPSSA, NP Thyroid 60, Ozempic, REZDIFFRA, Rybelsus, TEPEZZA, TZIELD, Tymlos, UNITHROID, Yorvipath, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error